

company announcement

Novo Nordisk A/S purchases B shares worth DKK 2,659 million from Novo Holdings A/S under the 2019 share repurchase programme

Bagsværd, Denmark, 5 November 2019 – Novo Nordisk A/S has today entered into an agreement to purchase 7,012,500 B shares of DKK 0.20 to a value of DKK 2,659 million from Novo Holdings A/S. This transaction is part of Novo Nordisk A/S' 2019 share repurchase programme of up to a total of DKK 15 billion to be executed during a 12-month period beginning 1 February 2019. The transaction price is DKK 379.14 per share and has been calculated as the three-day volume weighted average market price from 1 November to 5 November 2019 in the open window following the announcement of Novo Nordisk A/S' quarterly financial results.

Prior to the sale of B shares, Novo Holdings A/S' ownership of Novo Nordisk A/S was 28.3% of the share capital and 76.2% of the votes. Following the transaction, Novo Holdings A/S owns 537,436,000 A shares of DKK 0.20 and 135,764,000 B shares of DKK 0.20, corresponding to 28.1% of the capital and 76.1% of the votes in Novo Nordisk A/S.

The transaction is in line with the announcement on 1 November 2019 that Novo Holdings A/S intends to maintain its ownership of Novo Nordisk A/S' share capital around 28%.

With the transaction stated above, Novo Nordisk A/S owns a total of 44,982,955 B shares of DKK 0.20, corresponding to 1.9% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 of DKK 0.20 including treasury shares.

About Novo Holdings A/S

Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding and investment company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation's assets. Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. For further information please visit www.novoholdings.dk.

About Novo Nordisk A/S

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,200 people in 80 countries and markets its products in more than 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, [Facebook](#), [Twitter](#), [LinkedIn](#), [YouTube](#).

Further information*Novo Holdings Communication*

Christian Mostrup Scheel +45 3067 4805 cims@novo.dk

Novo Nordisk Media:

Anne Margrethe Hauge +45 4442 3450 amhg@novonordisk.com

Ken Inchausti (US) +1 609 240 9429 kiau@novonordisk.com

Novo Nordisk Investors:

Peter Hugrefte Ankersen +45 3075 9085 phak@novonordisk.com

Valdemar Borum Svarrer +45 3079 0301 jvls@novonordisk.com

Ann Søndermølle Rendbæk +45 3075 2253 arnd@novonordisk.com

Mark Joseph Root +45 3079 4211 mjhr@novonordisk.com

Kristoffer Due Berg (US) +1 609 235 2989 krdb@novonordisk.com